Andrea Crocker
Overview
Explore the profile of Andrea Crocker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
548
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Murphy M, Vitale L, ONeill T, Maurer D, Malenchek L, Crocker A, et al.
Allergy
. 2025 Feb;
PMID: 39976188
Background: Mast cells (MCs) respond to an array of allergens that drive allergic and inflammatory diseases. Stem cell factor (SCF), the ligand for the receptor KIT, is required for MC...
2.
Alvarado D, Maurer M, Gedrich R, Seibel S, Murphy M, Crew L, et al.
Allergy
. 2022 Feb;
77(8):2393-2403.
PMID: 35184297
Background: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients...
3.
Wasiuk A, Weidlick J, Sisson C, Widger J, Crocker A, Vitale L, et al.
Cancer Immunol Immunother
. 2021 May;
71(1):97-109.
PMID: 34028568
Cyclophosphamide plus fludarabine (C/F) are currently used to improve the expansion and effectiveness of adoptive cell therapy (ACT). However, these chemotherapeutics cause pan-leukopenia and adverse events, suggesting that safer and...
4.
Vitale L, He L, Thomas L, Wasiuk A, ONeill T, Widger J, et al.
Cancer Immunol Immunother
. 2020 May;
69(10):2125-2137.
PMID: 32451681
CD27 is a costimulatory molecule that provides a complementary target to the PD-1/PD-L1 checkpoint axis on T cells. Combining a CD27 agonist antibody with PD-1/PD-L1 blockade has shown synergistic antitumor...
5.
Vitale L, Thomas L, He L, ONeill T, Widger J, Crocker A, et al.
Cancer Immunol Immunother
. 2018 Nov;
68(2):233-245.
PMID: 30382327
Limitations of immunotherapy include poorly functioning events early in the immune response cycle, such as efficient antigen presentation and T cell priming. CD40 signaling in dendritic cells leads to upregulation...
6.
Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, et al.
J Immunol
. 2017 Nov;
199(12):4110-4123.
PMID: 29109120
CD27, a member of the TNFR superfamily, is constitutively expressed in most T cells and plays crucial roles in T cell effector functions. The costimulation and antitumor activity of CD27...
7.
Thomas L, Vitale L, ONeill T, Dolnick R, Wallace P, Minderman H, et al.
Mol Cancer Ther
. 2016 Sep;
15(12):2946-2954.
PMID: 27671527
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a type I transmembrane protein that was originally described as kidney injury molecule 1 (KIM-1) due to its elevated expression in kidney...
8.
Dhodapkar M, Sznol M, Zhao B, Wang D, Carvajal R, Keohan M, et al.
Sci Transl Med
. 2014 Apr;
6(232):232ra51.
PMID: 24739759
Immune-based therapies for cancer are generating substantial interest because of the success of immune checkpoint inhibitors. This study aimed to enhance anticancer immunity by exploiting the capacity of dendritic cells...
9.
He L, Prostak N, Thomas L, Vitale L, Weidlick J, Crocker A, et al.
J Immunol
. 2013 Sep;
191(8):4174-83.
PMID: 24026078
The CD70/CD27 pathway plays a significant role in the control of immunity and tolerance, and previous studies demonstrated that targeting murine CD27 (mCD27) with agonist mAbs can mediate antitumor efficacy....
10.
Vitale L, He L, Thomas L, Widger J, Weidlick J, Crocker A, et al.
Clin Cancer Res
. 2012 May;
18(14):3812-21.
PMID: 22589397
Purpose: The TNF receptor superfamily member CD27 is best known for its important role in T-cell immunity but is also recognized as a cell-surface marker on a number of B-...